Volume 14, Number 1—January 2008
Dispatch
Adamantane-Resistant Influenza Infection During the 2004–05 Season
Mahbubur Rahman*1, Rick A. Bright†2, Burney A. Kieke*, James G. Donahue*, Robert T. Greenlee*, Mary Vandermause*, Amanda Balish†, Angela Foust†, Nancy J. Cox†, Alexander I. Klimov†, David K. Shay†, and Edward A. Belongia*
Table 2
Demographic features of patients with adamantine-resistant or -susceptible influenza A, 2004–05 season*
| Variable | No. (%) resistant isolates, n = 72 | No. (%) susceptible isolates, n = 80 | Unadjusted prevalence ratio (95% CI) | Adjusted prevalence ratio (95% CI) |
|---|---|---|---|---|
| Age and high-risk status† | ||||
| 6–23 mo without high risk | 20 (74.1) | 7 (25.9) | 2.0 (1.3–3.0) | 2.1 (1.4–3.1) |
| 6–23 mo with high risk | 3 (50.0) | 3 (50.0) | 1.3 (0.6–3.2) | 1.4 (0.5–3.5) |
| 2–17 y with high risk | 8 (61.5) | 5 (38.5) | 1.7 (0.9–2.9) | 1.4 (0.8–2.4) |
| 18–49 y with high risk | 7 (36.8) | 12 (63.2) | 1.0 (0.5–2.0) | 0.9 (0.5–1.9) |
| 50–64 y with high risk | 8 (38.1) | 13 (61.9) | 1.0 (0.5–2.0) | 1.0 (0.6–1.9) |
| >65 y without high risk | 7 (46.7) | 8 (53.3) | 1.3 (0.7–2.4) | 1.2 (0.7–2.3) |
| >65 y with high risk | 19 (37.2) | 32 (62.8) | Referent group | Referent group |
| Sex | ||||
| Male | 37 (50.7) | 36 (49.3) | 1.1 (0.8–1.6) | 1.1 (0.8–1.5) |
| Female | 35 (44.3) | 44 (55.7) | Referent group | Referent group |
| Dates of clinical encounter | ||||
| 2005 Jan 3–23 | 10 (47.6) | 11 (52.4) | 0.9 (0.5–1.4) | 0.9 (0.5–1.5) |
| 2005 Jan 24–Feb 13 | 44 (55.0) | 36 (45.0) | Referent period | Referent period |
| 2005 Feb 14–Mar 6 | 15 (35.7) | 27 (64.3) | 0.6 (0.4–1.0) | 0.6 (0.4–1.0) |
| 2005 Mar 7–25 | 3 (33.3) | 6 (66.7) | 0.6 (0.2–1.6) | 0.5 (0.2–1.3) |
| Received 2004–05 influenza vaccine? | ||||
| Yes | 45 (42.9) | 60 (57.1) | 0.7 (0.5–1.0) | 0.8 (0.6–1.1) |
| No | 27 (57.4) | 20 (42.6) | Referent group | Referent group |
*CI, confidence interval.
†For the multivariate model, a composite variable was created based on age and the presence or absence of a high-risk medical condition as defined by Advisory Committee on Immunization Practices criteria.
Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.